Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar - CNBC
- Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar CNBC
- Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance Eli Lilly
- Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars Yahoo Finance
- Eli Lilly Profit Rises as Weight-Loss Drug Demand Surges The Wall Street Journal
- Eli Lilly rises on Q4 beat after Novo-led decline (LLY:NYSE) Seeking Alpha